Sugi Predict

Sugi Predict / Compounds / 2'-Deoxytubercidin

2'-Deoxytubercidin

2'-Deoxytubercidin

SCHEMBL7872094

Nc1ncnc2c1ccn2[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 5/20 0.57
▸ PRMT5 O14744 2/20 0.56
▸ ADK P55263 2/20 0.55
▸ HIF1A Q16665 1/20 0.52
▸ PNP P00491 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ ADORA3 P0DMS8 1/20 0.51
▸ ADORA2A P29274 1/20 0.51
▸ ADRB1 P08588 1/20 0.50
▸ DNMT1 P26358 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2'-Deoxytubercidin SCHEMBL5918784 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL7872096 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL13314431 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL23982116 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL14104716 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL23982321 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL3229680 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL14294692 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
2'-Deoxytubercidin SCHEMBL5918830 1.00 METTL3 (0.57) METTL3PRMT5ADKHIF1APNP
SCHEMBL21625244 0.91 METTL3 (0.60) METTL3PRMT5ADKADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025132708-A1 ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE PROQR THERAPEUTICS II B.V. (NL) 2025-06-26 — — WO claimed
CN-116916936-A Compositions and methods for delivering RNA 再生技术有限责任公司 2023-10-20 — — CN claimed
WO-2025132708-A1 ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE PROQR THERAPEUTICS II B.V. (NL) 2025-06-26 — — WO disclosed
CN-117343990-B Method and kit for determining target polynucleotide and probe set 牛津纳米孔科技公开有限公司 2025-05-30 — — CN disclosed
WO-2025104239-A1 ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CLASSIC GALACTOSEMIA PROQR THERAPEUTICS II B.V. (NL) 2025-05-22 — — WO disclosed
EP-4555086-A1 OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF ProQR Therapeutics II B.V. (NL) 2025-05-21 — — EP disclosed
CN-119789852-A Compositions and methods for delivering RNA 再生技术有限责任公司 2025-04-08 — — CN disclosed
WO-2025049632-A1 COMPOSITIONS AND METHODS FOR BROAD DELIVERY OF RNA TO TISSUE REJUVENATION TECHNOLOGIES INC. (US) 2025-03-06 — — WO disclosed
CN-118957041-A Method for determining polymer sequences 牛津纳米孔科技公开有限公司 2024-11-15 — — CN disclosed
CN-112703256-B Method for determining polymer sequences 牛津纳米孔科技公开有限公司 2024-09-03 — — CN disclosed
CN-117396193-A Compositions and methods for delivering RNA 再生技术有限责任公司 2024-01-12 — — CN disclosed
US-20150274767-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — US disclosed
US-20150274767-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — US disclosed
US-8481712-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. (US) 2013-07-09 — — US disclosed
US-8481712-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. (US) 2013-07-09 — — US disclosed
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2012-06-28 — — US disclosed
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2012-06-28 — — US disclosed
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. 2007-11-29 — — US disclosed
US-7202224-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2007-04-10 — — US disclosed
US-6312897-B1 RELATES TO TECHNIQUE FOR INHIBITING PROTEIN-ADENINE NONCOVALENT CONTACTS WITHOUT DISRUPTING SECONDARY STRUCTURE OF DNA, THEREBY PROVIDING TEMPLATE-DIRECTED INTERFERENCE TECHNIQUE FOR PRECISELY STUDYING PROTEIN-DNA INTERACTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2001-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT METTL3 218/4885PRMT5 436/4885ADK 239/4885
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT METTL3 218/4885PRMT5 436/4885ADK 239/4885
US-20150274767-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS DUT, HPRT1, RNGTT METTL3 624/4885PRMT5 151/4885ADK 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.